%0 Journal Article
%T Comparison of long-term anti-RBD SARS-CoV-2 antibody response following different vaccination schemes in Tunisia.
%A Ben Jemaa A
%A Bouabsa R
%A Ben Othmen M
%A Oueslati R
%A Dhaouadi H
%J Tunis Med
%V 102
%N 8
%D 2024 Aug 5
%M 39129572
暂无%R 10.62438/tunismed.v102i8.4944
%X <B>OBJECTIVE: </B>The study aimed to compare long-term vaccine-induced humoral immunity following different vaccines regimens.<BR><B>METHODS: </B>Anti-S-RBD total antibody levels were measured in blood samples of 167 participants nearly 6 months post-vaccination. Participants had received one; two or four doses of Pfizer vaccine or who received a third dose of mRNA vaccine (Pfizer) and primed with mRNA (Pfizer/Moderna), adenoviral (AstraZeneca/Jonson & Jonson) or inactivated (CoronaVac/Sinopharm) vaccine.<BR><B>RESULTS: </B>Among all vaccination regimens, fourth dose of Pfizer achieved the highest S-RBD antibody titers. Nevertheless, the third dose of mRNA vaccine primed with adenoviral vaccine achieved the lowest titers of S-RBD antibody. Notably, the group that received a third dose of mRNA primed with two doses of mRNA vaccine exhibited higher S-RBD antibody compared to groups inoculated with a third dose of mRNA and primed with inactivated or adenovirus vaccine.<BR><B>CONCLUSIONS: </B>Our data showed the superiority of three mRNA vaccinations compared to third heterologous vaccine (inactivated of adenoviral) including mRNA as booster in terms of humoral immunogenicity. Our findings supporting the use of additional booster shot from a more potent vaccine type such as mRNA vaccines. Nevertheless, due to the limited number of subjects, it is difficult to extrapolate the results of our study to the whole of Tunisian population. Future studies should investigate a larger cohort and other potential correlates of protection, such as cellular immunity and how it is affected by different vaccination schemes after long-term post-vaccination.